OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Molecular Characterization ofKRASWild-type Tumors in Patients with Pancreatic Adenocarcinoma
Philip A. Philip, Ibrahim Azar, Joanne Xiu, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 12, pp. 2704-2714
Open Access | Times Cited: 117
Philip A. Philip, Ibrahim Azar, Joanne Xiu, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 12, pp. 2704-2714
Open Access | Times Cited: 117
Showing 1-25 of 117 citing articles:
Pancreatic cancer: Advances and challenges
Christopher J. Halbrook, Costas A. Lyssiotis, Marina Pasca di Magliano, et al.
Cell (2023) Vol. 186, Iss. 8, pp. 1729-1754
Open Access | Times Cited: 529
Christopher J. Halbrook, Costas A. Lyssiotis, Marina Pasca di Magliano, et al.
Cell (2023) Vol. 186, Iss. 8, pp. 1729-1754
Open Access | Times Cited: 529
Neoadjuvant therapy for pancreatic cancer
Christoph Springfeld, Cristina R. Ferrone, Matthew H. G. Katz, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 5, pp. 318-337
Closed Access | Times Cited: 205
Christoph Springfeld, Cristina R. Ferrone, Matthew H. G. Katz, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 5, pp. 318-337
Closed Access | Times Cited: 205
Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Thierry Conroy, Per Pfeiffer, Valérie Vilgrain, et al.
Annals of Oncology (2023) Vol. 34, Iss. 11, pp. 987-1002
Open Access | Times Cited: 174
Thierry Conroy, Per Pfeiffer, Valérie Vilgrain, et al.
Annals of Oncology (2023) Vol. 34, Iss. 11, pp. 987-1002
Open Access | Times Cited: 174
Therapeutic developments in pancreatic cancer
Zilun Hu, Eileen M. O’Reilly
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 21, Iss. 1, pp. 7-24
Closed Access | Times Cited: 123
Zilun Hu, Eileen M. O’Reilly
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 21, Iss. 1, pp. 7-24
Closed Access | Times Cited: 123
The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma
Daniel J. Renouf, Jonathan M. Loree, Jennifer J. Knox, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 71
Daniel J. Renouf, Jonathan M. Loree, Jennifer J. Knox, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 71
Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer
Dimitrios Stefanoudakis, Maximos Frountzas, Dimitriοs Schizas, et al.
Current Issues in Molecular Biology (2024) Vol. 46, Iss. 4, pp. 2827-2844
Open Access | Times Cited: 20
Dimitrios Stefanoudakis, Maximos Frountzas, Dimitriοs Schizas, et al.
Current Issues in Molecular Biology (2024) Vol. 46, Iss. 4, pp. 2827-2844
Open Access | Times Cited: 20
Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer
Alison M. Schram, Kōichi Goto, Dong-Wan Kim, et al.
New England Journal of Medicine (2025) Vol. 392, Iss. 6, pp. 566-576
Closed Access | Times Cited: 5
Alison M. Schram, Kōichi Goto, Dong-Wan Kim, et al.
New England Journal of Medicine (2025) Vol. 392, Iss. 6, pp. 566-576
Closed Access | Times Cited: 5
Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer
Harshabad Singh, Rachel B. Keller, Kevin S. Kapner, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 22, pp. 4627-4643
Open Access | Times Cited: 27
Harshabad Singh, Rachel B. Keller, Kevin S. Kapner, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 22, pp. 4627-4643
Open Access | Times Cited: 27
Next-generation therapies for pancreatic cancer
Conor Buckley, Eileen M. O’Reilly
Expert Review of Gastroenterology & Hepatology (2024) Vol. 18, Iss. 1-3, pp. 55-72
Open Access | Times Cited: 12
Conor Buckley, Eileen M. O’Reilly
Expert Review of Gastroenterology & Hepatology (2024) Vol. 18, Iss. 1-3, pp. 55-72
Open Access | Times Cited: 12
Inhibition of the RAF/MEK/ERK Signaling Cascade in Pancreatic Cancer: Recent Advances and Future Perspectives
Christos Adamopoulos, Donatella Delle Cave, Athanasios G. Papavassiliou
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 3, pp. 1631-1631
Open Access | Times Cited: 9
Christos Adamopoulos, Donatella Delle Cave, Athanasios G. Papavassiliou
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 3, pp. 1631-1631
Open Access | Times Cited: 9
Fusion genes in pancreatic tumors
Αναστάσιος Γκουντάκος, Aatur D. Singhi, C. Benedikt Westphalen, et al.
Trends in cancer (2024) Vol. 10, Iss. 5, pp. 430-443
Open Access | Times Cited: 9
Αναστάσιος Γκουντάκος, Aatur D. Singhi, C. Benedikt Westphalen, et al.
Trends in cancer (2024) Vol. 10, Iss. 5, pp. 430-443
Open Access | Times Cited: 9
Ferroptosis and EMT resistance in cancer: a comprehensive review of the interplay
Huiming Zhang, Naifeng Chen, Chenglong Ding, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 8
Huiming Zhang, Naifeng Chen, Chenglong Ding, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 8
Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival
Anna M. Varghese, Maria Perry, Joanne F. Chou, et al.
Nature Medicine (2025)
Open Access | Times Cited: 1
Anna M. Varghese, Maria Perry, Joanne F. Chou, et al.
Nature Medicine (2025)
Open Access | Times Cited: 1
Integrative analysis of KRAS wildtype metastatic pancreatic ductal adenocarcinoma reveals mutation and expression-based similarities to cholangiocarcinoma
James T. Topham, Erica S. Tsang, Joanna M. Karasinska, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 29
James T. Topham, Erica S. Tsang, Joanna M. Karasinska, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 29
Precision medicine for KRAS wild-type pancreatic adenocarcinomas
Imen Ben-Ammar, Adrien Rousseau, Rémy Nicolle, et al.
European Journal of Cancer (2023) Vol. 197, pp. 113497-113497
Closed Access | Times Cited: 19
Imen Ben-Ammar, Adrien Rousseau, Rémy Nicolle, et al.
European Journal of Cancer (2023) Vol. 197, pp. 113497-113497
Closed Access | Times Cited: 19
Biological characteristics of pancreatic ductal adenocarcinoma: Initiation to malignancy, intracellular to extracellular
Ou Li, Li Li, Yunru Sheng, et al.
Cancer Letters (2023) Vol. 574, pp. 216391-216391
Open Access | Times Cited: 18
Ou Li, Li Li, Yunru Sheng, et al.
Cancer Letters (2023) Vol. 574, pp. 216391-216391
Open Access | Times Cited: 18
Targeting KRAS in Pancreatic Ductal Adenocarcinoma: The Long Road to Cure
Victor Hugo Fonseca de Jesus, Maria Cecília Mathias-Machado, João Paulo Fogacci de Farias, et al.
Cancers (2023) Vol. 15, Iss. 20, pp. 5015-5015
Open Access | Times Cited: 17
Victor Hugo Fonseca de Jesus, Maria Cecília Mathias-Machado, João Paulo Fogacci de Farias, et al.
Cancers (2023) Vol. 15, Iss. 20, pp. 5015-5015
Open Access | Times Cited: 17
Genetic Signature of Human Pancreatic Cancer and Personalized Targeting
Stephan J. Reshkin, Rosa Angela Cardone, Tomas Koltai
Cells (2024) Vol. 13, Iss. 7, pp. 602-602
Open Access | Times Cited: 7
Stephan J. Reshkin, Rosa Angela Cardone, Tomas Koltai
Cells (2024) Vol. 13, Iss. 7, pp. 602-602
Open Access | Times Cited: 7
KRAS G12D Mutation Subtype in Pancreatic Ductal Adenocarcinoma: Does It Influence Prognosis or Stage of Disease at Presentation?
Henry Shen, Joanne Lundy, Andrew Strickland, et al.
Cells (2022) Vol. 11, Iss. 19, pp. 3175-3175
Open Access | Times Cited: 25
Henry Shen, Joanne Lundy, Andrew Strickland, et al.
Cells (2022) Vol. 11, Iss. 19, pp. 3175-3175
Open Access | Times Cited: 25
Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies
Anthony Turpin, Cindy Neuzillet, Elise Colle, et al.
Therapeutic Advances in Medical Oncology (2022) Vol. 14
Open Access | Times Cited: 22
Anthony Turpin, Cindy Neuzillet, Elise Colle, et al.
Therapeutic Advances in Medical Oncology (2022) Vol. 14
Open Access | Times Cited: 22
A Simple Overview of Pancreatic Cancer Treatment for Clinical Oncologists
Ingrid Garajová, Marianna Peroni, Fabio Gelsomino, et al.
Current Oncology (2023) Vol. 30, Iss. 11, pp. 9587-9601
Open Access | Times Cited: 15
Ingrid Garajová, Marianna Peroni, Fabio Gelsomino, et al.
Current Oncology (2023) Vol. 30, Iss. 11, pp. 9587-9601
Open Access | Times Cited: 15
Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunichLMU Molecular Tumor Board
Klara Dorman, Danmei Zhang, Kathrin Heinrich, et al.
Targeted Oncology (2023) Vol. 18, Iss. 2, pp. 257-267
Open Access | Times Cited: 13
Klara Dorman, Danmei Zhang, Kathrin Heinrich, et al.
Targeted Oncology (2023) Vol. 18, Iss. 2, pp. 257-267
Open Access | Times Cited: 13
Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment
Szu-Aun Long, Amber M. Amparo, Grace Goodhart, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 5
Szu-Aun Long, Amber M. Amparo, Grace Goodhart, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 5
The trend toward more target therapy in pancreatic ductal adenocarcinoma
Chiara Deiana, Margherita Agostini, Giovanni Brandi, et al.
Expert Review of Anticancer Therapy (2024) Vol. 24, Iss. 7, pp. 525-565
Open Access | Times Cited: 5
Chiara Deiana, Margherita Agostini, Giovanni Brandi, et al.
Expert Review of Anticancer Therapy (2024) Vol. 24, Iss. 7, pp. 525-565
Open Access | Times Cited: 5
Elucidating the therapeutic potential of indazole derivative bindarit against K-ras receptor: An in-silico analysis using molecular dynamics exploration
Parmar Keshri Nandan, Sivaraman Jayanthi
Biochemistry and Biophysics Reports (2025) Vol. 41, pp. 101913-101913
Closed Access
Parmar Keshri Nandan, Sivaraman Jayanthi
Biochemistry and Biophysics Reports (2025) Vol. 41, pp. 101913-101913
Closed Access
